SCYX vs. ETTX, NBRV, NLTX, NKTX, STTK, AVIR, ORGO, SKYE, EBS, and SBTX
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Entasis Therapeutics (ETTX), Nabriva Therapeutics (NBRV), Neoleukin Therapeutics (NLTX), Nkarta (NKTX), Shattuck Labs (STTK), Atea Pharmaceuticals (AVIR), Organogenesis (ORGO), Skye Bioscience (SKYE), Emergent BioSolutions (EBS), and Silverback Therapeutics (SBTX). These companies are all part of the "medical" sector.
SCYNEXIS (NASDAQ:SCYX) and Entasis Therapeutics (NASDAQ:ETTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 6.9% of Entasis Therapeutics shares are held by institutional investors. 2.9% of SCYNEXIS shares are held by insiders. Comparatively, 6.5% of Entasis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
SCYNEXIS has higher revenue and earnings than Entasis Therapeutics. Entasis Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
SCYNEXIS currently has a consensus target price of $15.00, indicating a potential upside of 588.07%. Given SCYNEXIS's higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Entasis Therapeutics.
SCYNEXIS has a net margin of 72.18% compared to Entasis Therapeutics' net margin of 0.00%. SCYNEXIS's return on equity of 112.89% beat Entasis Therapeutics' return on equity.
SCYNEXIS has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Entasis Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
SCYNEXIS received 409 more outperform votes than Entasis Therapeutics when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 64.86% of users gave Entasis Therapeutics an outperform vote.
In the previous week, SCYNEXIS's average media sentiment score of 0.00 equaled Entasis Therapeutics'average media sentiment score.
Summary
SCYNEXIS beats Entasis Therapeutics on 13 of the 15 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SCYNEXIS Competitors List
Related Companies and Tools
